Comparative Pharmacology
Head-to-head clinical analysis: ALFENTA versus CONZIP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALFENTA versus CONZIP.
ALFENTA vs CONZIP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing cAMP production, leading to reduced neuronal excitability and pain transmission.
Tramadol hydrochloride (opioid agonist) and acetaminophen (centrally acting analgesic). Tramadol binds to mu-opioid receptors and inhibits serotonin and norepinephrine reuptake; acetaminophen inhibits cyclooxygenase (COX) and activates descending serotonergic pathways.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
100 mg to 300 mg orally once daily with food. Initiate at 100 mg daily and titrate up by 100 mg increments every 4-7 days based on tolerability. Maximum dose 300 mg daily.
None Documented
None Documented
Clinical Note
moderateAlfentanil + Torasemide
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Torasemide."
Clinical Note
moderateAlfentanil + Etacrynic acid
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Etacrynic acid."
Clinical Note
moderateAlfentanil + Furosemide
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Furosemide."
Clinical Note
moderateAlfentanil + Bumetanide
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Terminal elimination half-life: 3-4 hours for tramadol, 5-9 hours for M1 metabolite; clinically, dosing interval is 4-6 hours
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
~60% renal (unchanged drug and glucuronide conjugates), ~35% fecal
Category C
Category C
Opioid Analgesic
Opioid Analgesic
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Bumetanide."